Form 4: Verve Therapeutics Executive Granted Stock Options and Restricted Stock Units

Joan Nickerson, Chief Administrative Officer of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025.

Summary

• Joan Nickerson, Chief Administrative Officer at Verve Therapeutics, received stock options for 225,000 shares at an exercise price of $6.01 on January 8, 2025.
• These options vest over a four-year period, with 25% vesting on January 8, 2026, and the remainder vesting monthly until January 8, 2029.
• Additionally, Nickerson was granted 40,000 restricted stock units (RSUs) on the same date.
• These RSUs vest in three equal annual installments starting on April 1, 2026, with subsequent vesting dates on April 1, 2027, and April 1, 2028.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Verve Therapeutics' stock price.
• There is a risk that the executive may leave the company before the options and RSUs fully vest.

Future Outlook

The vesting schedules for the stock options and RSUs are designed to incentivize long-term performance and retention of the executive.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key talent.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry, similar to companies like CRISPR Therapeutics and Editas Medicine.
• The vesting schedules are typical, with a mix of time-based vesting over several years to align with long-term company goals.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, vesting, Verve Therapeutics, equity